The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size
- PMID: 19399265
- PMCID: PMC2672123
- DOI: 10.3346/jkms.2009.24.2.242
The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size
Abstract
In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study.
Keywords: Carcinoma, Hepatocellular; Hepatic Resection; Radiotherapy; TACE.
Figures
Similar articles
-
Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma.Korean J Hepatol. 2010 Dec;16(4):383-8. doi: 10.3350/kjhep.2010.16.4.383. Korean J Hepatol. 2010. PMID: 21415582 Free PMC article. Clinical Trial.
-
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044767 Free PMC article.
-
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.Am J Clin Oncol. 2003 Aug;26(4):e92-9. doi: 10.1097/01.COC.0000077936.97997.AB. Am J Clin Oncol. 2003. PMID: 12902905 Clinical Trial.
-
Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.Oncotarget. 2017 Jan 3;8(1):408-417. doi: 10.18632/oncotarget.13427. Oncotarget. 2017. PMID: 27880724 Free PMC article.
-
Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.BMC Cancer. 2016 Nov 3;16(1):834. doi: 10.1186/s12885-016-2894-9. BMC Cancer. 2016. PMID: 27809890 Free PMC article.
Cited by
-
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13. Korean J Radiol. 2015. PMID: 25995680 Free PMC article.
-
Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort.Onco Targets Ther. 2016 Jun 23;9:3783-9. doi: 10.2147/OTT.S105192. eCollection 2016. Onco Targets Ther. 2016. PMID: 27382314 Free PMC article.
-
Effect of curcumin-lipiodol emulsion combined with absorbable anti-adhesion film through double embolic pathway on angiogenesis and overall survival (OS) time of VX2 liver cancer rabbits.Transl Cancer Res. 2020 Feb;9(2):742-753. doi: 10.21037/tcr.2019.12.15. Transl Cancer Res. 2020. PMID: 35117420 Free PMC article.
-
Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.Yonsei Med J. 2014 Nov;55(6):1489-97. doi: 10.3349/ymj.2014.55.6.1489. Yonsei Med J. 2014. PMID: 25323884 Free PMC article.
-
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy.J Immunother Cancer. 2020 Nov;8(2):e000932. doi: 10.1136/jitc-2020-000932. J Immunother Cancer. 2020. PMID: 33219090 Free PMC article.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153–156. - PubMed
-
- Annual report on the cause of death statistics. Korean statistical information system. Available at: http://kosis.kr.
-
- Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S. Hepatic resection for hepatocellular carcinoma--Japanese experience. Hepatogastroenterology. 1998;45:1267–1274. - PubMed
-
- Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K. Hepatic resection for hepatocellular carcinoma. Surgery. 1990;107:511–520. - PubMed
-
- Kim SS, Lee CD, Choi SW, Han NI, Kim JI, Han SW, Yoon SK, Yang JM, Park YM, Han SW, Lee YS, Park DH, Kim BS. Prognosis and prognostic factors in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Gastroenterol. 1997;30:72–80.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous